- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
- Interventions
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Drug · Diagnostic Test
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 877
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Cancer Related Fatigue
- Interventions
- EXCAP Exercise Program, 10-Hour Healthy Eating Timeframe (hEAT)
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
- Interventions
- TRX518, Cyclophosphamide, Avelumab
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more
- Conditions
- Diabetes
- Interventions
- Continuous Glucose Monitoring System (CGMS), Food log
- Device · Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes
- Interventions
- Bionic Pancreas, Usual Care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
- Interventions
- Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
- Interventions
- Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Toremifene Citrate
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 60 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 1 Diabetes
- Interventions
- FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- HIV, Depression, Cannabis Use Disorder, Stress, Pain
- Interventions
- Yale Pain Stress Task (YPST)
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole, Questionnaire Administration, Tamoxifen Citrate
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 521
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more
- Conditions
- Breast Cancer
- Interventions
- Lapatinib, Trastuzumab, Endocrine
- Drug
- Lead sponsor
- Baylor Breast Care Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Shwachman-Diamond Syndrome
- Interventions
- Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires
- Diagnostic Test · Other · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
- Interventions
- Continuous Glucose Monitoring with treatment algorithm
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Chapel Hill, North Carolina
- Conditions
- Breast Cancer, Adherence, Medication
- Interventions
- STRIDE, Medication Monitoring Control
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Months and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- antineoplaston A10, antineoplaston AS2-1, bicalutamide, flutamide, leuprolide acetate, alternative product therapy, antiandrogen therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy, endocrine therapy, hormone therapy
- Drug · Procedure
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer Female
- Interventions
- Behavioral Intervention., Nutritional Education.
- Behavioral · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Graves Disease
- Interventions
- BHV-1300
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- South Gate, California • Miami, Florida • Columbus, Georgia + 6 more
- Conditions
- Breast, Breast Cancer, Osteoporosis
- Interventions
- High Dose Vitamin D, Standard of Care Vitamin D
- Dietary Supplement
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Continuous Glucose Monitoring Sensor, Diabetes Management Instructions
- Device · Other
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non Alcoholic Fatty Liver Disease
- Interventions
- ogtt, genotyping, abdominal and liver magnetic resonance imaging, stool sample, liver biopsy
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes Treated With Insulin
- Interventions
- Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS), Continuous Glucose Monitor (CGM) + Usual Care
- Other
- Lead sponsor
- Daniel Chernavvsky, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Metastatic Cancer, Prostate Cancer
- Interventions
- Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate, Zoledronic acid, orchiectomy, strontium chloride Sr
- Drug · Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Wichita, Kansas • Houston, Texas + 1 more